---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031390"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:15:26.785022+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports Q3 2023 cash of $24.6M; advances Annamycin in AML and STS

## Summary
- Cash and equivalents $24.6M as of Sep 30, 2023; runway estimated into Q3 2024.
- R&D expense $3.3M, down 45% YoY from $6.0M; G&A $2.6M, down 16% from $3.1M.
- Dosed first subjects in Phase 2 trial of Annamycin + Cytarabine for AML (MB106).
- Completed enrollment in U.S. Phase 1b/2 trial of Annamycin for STS lung metastases (MB107).
- Independent assessment confirmed absence of cardiotoxicity in Annamycin-treated subjects.

## SEC filing metadata
- accession: 0001437749-23-031390
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/0001437749-23-031390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/mbrx20231109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031390
- JSON: https://secwatch.observer/filing/0001437749-23-031390.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031390.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/0001437749-23-031390-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.